Recent studies show that patients with the most serious forms of the coronavirus had high levels of IL-6, a common inflammatory cytokine, which MediSieve has previously encountered while researching sepsis and cytokine storms.
Finding a way to selectively and rapidly target and remove IL-6 from COVID-19 patients’ bloodstream could be extremely beneficial.
Currently, the majority of severe COVID-19 patients are treated with immunoblockers or immunosuppressants. While still effective treatments, their most dangerous drawback is that the suppressants stay in the bloodstream, leaving patients immunsupressed while fighting the infection.